For long-term secondary prevention of MI, the use of P2Y12 monotherapy has a borderline advantage over aspirin alone and does not affect bleeding, according to a meta-analysis of nine randomized ...

Please provide your email address to receive an email when new articles are posted on . Valgimigli is deputy chief of interventional cardiology at Cardiocentro Ticino Institute, Lugano, Switzerland.

In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation ...

BARCELONA -- Patients with documented coronary artery disease (CAD) saw cardiovascular benefits with P2Y12-inhibitor monotherapy when compared with aspirin alone, according to the PANTHER ...

Background: The initial results for CURRENT-OASIS 7 were presented at the European Society of Cardiology Congress 2009 in Barcelona. To date, final analyses of the study have not been published in a ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

How much do we know about the way blood clots? We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...